Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Celldex Presents Positive First-in-Human Results From Phase 1 Study of Novel Bispecific CDX-622 ...

Summary by Hastings Tribune
CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functionsRapid, profound,…

2 Articles

Hastings TribuneHastings Tribune
Center

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 ...

CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurably impacting other KIT functionsRapid, profound,…

·Nebraska, United States
Read Full Article
stocktitan.netstocktitan.net

New Celldex antibody depletes mast cells in first human test

Bispecific CDX-622 neutralizes soluble SCF and TSLP, depleting mast cells without serious adverse events; a Phase 1b asthma study is underway.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news on Sunday, June 14, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Hastings, Nebraska icon

Hastings, Nebraska

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal